Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients-Reference-Cited by-同舟云学术

Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients

Published:2021-03-01 Issue:4 Volume:21 Page:467-475
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Alshaikheid Mohammed^ORCID,Ben Fredj Nadia,Hannachi Ibtissem,Kolsi Naourez,Ben Fadhel Najah,Kerkeni Emna,Ben Romdhane Haifa,Chaabane Amel,Koubaa Jamel,Chadli Zohra,Aouam Karim

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/s41397-021-00223-x.pdf

Reference31 articles.

1. Mostowy S, Behr MA. The origin and evolution of Mycobacterium tuberculosis. Clin Chest Med. 2005;26:207–16.

2. WHO. Global tuberculosis report 2018 WHO. Available from: http://www.who.int/tb/publications/global_report/en/. Accessed 2 Aug 2020.

3. DSSB. Minister of Public Health. Le guide national de prise en charge de la tuberculose édition 2018. Available from: http://www.santetunisie.rns.tn/fr/toutes-les-actualites/807-dssb-le-guide-national-de-prise-en-charge-de-la-tuberculose-%C3%A9dition-2018. Accessed 2 Aug 2020.

4. WHO. International Standards for Tuberculosis Care (ISTC). Available from: http://www.who.int/tb/publications/2006/istc/en/. Accessed 2 Aug 2020.

5. Sturkenboom MGG, Akkerman OW, Altena R, van, Lange WCM, de, Kosterink JGW, Werf TSvan der . et al. Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. Eur Respir J. 2016;48:1237–9.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review;Clinical and Translational Science;2024-04

2. Population pharmacokinetics/toxicokinetics;Public Health and Toxicology Issues Drug Research, Volume 2;2024

3. Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility;Tuberculosis;2023-07

4. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models;European Journal of Clinical Pharmacology;2022-07-19

5. Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management;Pharmaceutics;2022-05-05